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A large number of cardiovascular events are not prevented by current therapeutic regimens. In search for additional, innovative strategies,
immune cells have been recognized as key players contributing to atherosclerotic plaque progression and destabilization. Particularly the
role of innate immune cells is of major interest, following the recent paradigm shift that innate immunity, long considered to be incapable
of learning, does exhibit immunological memory mediated via epigenetic reprogramming. Compelling evidence shows that atherosclerotic
risk factors promote immune cell migration by pre-activation of circulating innate immune cells. Innate immune cell activation via meta-
bolic and epigenetic reprogramming perpetuates a systemic low-grade inflammatory state in cardiovascular disease (CVD) that is also
common in other chronic inflammatory disorders. This opens a new therapeutic area in which metabolic or epigenetic modulation of
innate immune cells may result in decreased systemic chronic inflammation, alleviating CVD, and its co-morbidities.
...................................................................................................................................................................................................
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Introduction
Cardiovascular diseases (CVD) are a major health challenge for
modern societies. An estimated number of 17 million people die due
to CVD each year, representing 30% of all deaths worldwide.
The high burden of CVD is attributable to the increasing incidence of
atherosclerosis, caused amongst others by worldwide adoption
of the Western lifestyle.1 In parallel, the incidence of chronic
inflammatory diseases (CID) such as rheumatoid arthritis (RA) is
rising. Since CID are accompanied by a two- to three-fold higher
CVD-risk,2 the increased CID prevalence further contributes to
the overall CVD burden. Traditionally, risk factors for atherosclerosis
are considered to be dyslipoproteinaemia, as well as smoking,
hypertension, diabetes, and obesity. Subsequently, therapeutic
measures have focused on lowering the most atherogenic choles-
terol, predominantly low-density-lipoprotein cholesterol (LDL-C),
which has successfully lowered CVD-risk by 25–35%.3 This
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success rate, however, also discloses a large residual risk not
adequately addressed by current cholesterol-lowering treatment
alone.
Atherosclerosis is a chronic
inflammatory disease
Atherosclerosis, formerly considered a lipid storage disease, involves
a chronic, low-grade inflammatory response of the arterial wall, initi-
ated by lipid accumulation in the intimal layer.4 Low-density-lipopro-
tein-cholesterol or modified LDL-cholesterol can trigger pattern-
recognition receptors, including toll-like receptors (TLRs).5
Subsequent activation and recruitment of innate immune cells con-
tributes to plaque progression and eventually plaque destabilization.6
In more detail, it has been demonstrated that following accumulation
of cholesterol in the arterial wall, the subendothelial lipids are modi-
fied leading to the formation of active signalling moieties. Particularly
oxidized derivatives and cholesterol crystals7 trigger a variety of in-
flammatory pathways, immune cells and mediators8 that drive ath-
erogenesis and co-morbidities of this disease. As the atherosclerotic
lesion advances, the presence of immune cells in the lesion increases
proportionally, creating a localized pro-inflammatory milieu within
the subendothelial compartment.9 Cholesterol crystal uptake in mac-
rophages for example promotes atherosclerosis and more impor-
tantly destabilization of the plaques via TLR-4 activation.5
Accumulation of cholesterol not only activates a pro-inflammatory
response. Upon accumulation, the reverse cholesterol transporters
ABCA1 and ABCG1 are upregulated via the LXR–RXR pathway.5
ABCA1 and ABCG1 subsequently promote the efflux of cholesterol
from macrophages.10 Unfortunately, this negative feedback loop is
not sufficient enough to prevent the activation of the immune
system.
In addition to excessive amounts of lipids, atherosclerotic lesions
thus harbour all classes of immune cells and moreover, serum levels
of inflammatory mediators are linked to coronary heart disease.11
Recent advances in preclinical research have established a fundamen-
tal role for cellular inflammation throughout all stages of this disease
from initiation through progression and, ultimately, the thrombotic
complications following plaque rupture or erosion.6,12–14 A key role
for innate immunity is illustrated by studies showing that monocytes
and macrophages are abundantly present in atherosclerotic
plaques,15 and moreover, inhibiting monocyte-entry into the plaque
drastically attenuates atherogenesis16 as well as CVD-risk,9 whereas
immune cell stimulation accelerates atherosclerosis.13
In parallel, systemic monocyte production and circulating mono-
cyte number increase progressively with advancing disease.17,18
These innate immune cells help drive the formation of an extensive
microvascular network penetrating the more advanced atheroscle-
rotic lesions. These leaky, immature vessels provide an easy commu-
nication and access network for both cellular as well as humoral
elements.19 The extravasated immune cells also have an intricate im-
pact on plaque phenotype by contributing substantially to endothelial
dysfunction, oxidative stress, and extracellular matrix degradation.9
From a therapeutic perspective, several randomized clinical trials are
currently underway that will determine whether non-specific anti-
inflammatory therapies with for instance interleukin-1-neutralizing
antibodies or methotrexate can reduce the risk of cardiovascular
events in patients with atherosclerosis.20–22
To date, little is known on the mechanism(s) maintaining the
chronic inflammatory state in CV patients. Recent data have moved
our focus from immune cells within the atherosclerotic plaque to-
wards a systemic pro-inflammatory state, characterized by increased
production and mobilization of innate immune cells by haemato-
poietic organs,7,13,23 lipoprotein-driven activation of innate immune
cells already within the plasma compartment,24 and rapid, increased
influx of immune cells into atherosclerotic plaques in patients,25
collectively driving the inflammatory state in the atherosclerotic
plaque.
Whereas the contribution of immune cells to atherogenesis has
been well established, it remains elusive why the strong inflammatory
response in the arterial wall persists over time. In the adaptive arm
of the immune system, dendritic cells in the plaque promote adaptive
immune responses by presenting antigens, leading to enhanced T-cell
function both in experimental and clinical atherosclerosis.26 The
interplay between activated T-cells and resident macrophages
perpetuates a local inflammatory cascade within the subendothelial
compartment.4,27 In addition, increasing body of evidence directs
towards a role for impaired resolution of inflammation.28–30
From a therapeutic standpoint, however, interventions targeting
the adaptive immune system directly are hampered by a markedly in-
creased incidence of infectious complications.31,32 A better under-
standing of the role of the innate immune system in the chronic
inflammatory characteristics of atherosclerosis may overcome these
limitations. However, boosting the adaptive immune system using
vaccination strategies has therapeutic potential and is currently being
studied for atherosclerosis treatment.26,33
Multi-level systemic immune cell
activation contributes to
atherogenesis and cardiovascular
risk
The challenges in targeting inflammation in any chronic disease lie in
three properties that are critical for evolutionary survival: redun-
dancy, compensation, and necessity. Targeting one component may
not be sufficient to attenuate a pro-inflammatory reaction.
Inflammation is a carefully tuned process that has multiple feedback
loops: thus, inhibition of a critical pathway may trigger a compensa-
tory pro-inflammatory response. Finally and most importantly, the in-
flammatory response is critical for host defence, and even if the
previous two challenges have been met, the risk–benefit ratio may
still be unacceptable, exposing for example to an elevated risk
of infections. Accordingly, broad immune pathway targeting is
unlikely to confer therapeutic benefits. Therefore, developing
anti-inflammatory therapies involves identifying suitable pathways
in mice, pre-clinical testing of whether the pathway can be
neutralized without causing collateral damage, translational studies
identifying similarly relevant pathways in humans, and, finally, clinical
trials. This challenging drug discovery path can be negotiated more
3522 R.M. Hoogeveen et al.
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efficiently with the help of immune system imaging, especially of
immune cells, their subsets, and their migration, production, and
function.
The rate of progression of atherosclerotic lesions is critically
dependent on the number and characteristics of the circulating
monocyte pool.34 In view of the short half-life of innate immune
cells,14 attention has shifted towards a more prominent role of bone
marrow mobilization and activation of immune cell progenitors13 and
local proliferation.14 Recently, acute events, both myocardial infarc-
tion13 and stroke35 were found to elicit a spike in neutrophil and
monocyte production in experimental models, which subsequently
accumulated in the infarcted areas. In apoE-/- mice with advanced
atherosclerosis, acute local events were also found to augment in-
flammation in atherosclerotic plaques at a distance, increasing plaque
size, and inducing a more vulnerable lesion morphology with higher
inflammatory cell content. An increased supply of innate immune
cells was identified as the principal driver for this phenomenon.13
However, the residence time of innate immune cells in ischaemic tis-
sue was estimated to be 19 h, implying the continued need for new
immune cells to maintain the high cell number in atherosclerotic le-
sions.36 To support this demand, in mice after coronary ligation, in-
creased sympathetic nervous activity released upstream precursors
from bone marrow niches.13 Markedly, both the increased monocyte
count and the pro-inflammatory changes in systemic plaques per-
sisted for several months, the mechanism for which remains yet to be
established.
Haematopoiesis in the bone marrow produces most of the circu-
lating monocytes in human. Dysregulated haematopoiesis in the
bone marrow can be caused by several stimuli, among which
dyslipidaemia.37,38 Biased differentiation of the haematopoietic stem
cells (HSCs) can, in the case of dyslipidaemia, increase monocyte
production. The number of circulating innate immune cells was
shown to be a strong predictor of future CV-risk in patients.39
Following an acute myocardial infarction (AMI), bone marrow activ-
ity as well as inflammatory signals in distant atherosclerotic le-
sions were found to be increased,23 implying a systemic cellular
mobilization comparable to experimental data.13 In advanced athero-
sclerotic lesions, immune cell accumulation is also markedly in-
creased, implying a role for systemic immune cell activity in
maintaining the increased inflammatory state in the arterial wall.25
Furthermore, not only the monocyte number, but also the monocyte
phenotype may be affecting atherogenesis. In vitro, several athero-
genic risk factors were shown to induce a persistent activated state in
monocytes,40 which can further contribute to arterial wall
inflammation.
Somatic mutations in HSCs are commonly found in the general
population, especially in increasing age categories; in the group of
people above 70 years of age 10% have somatic mutations. Mutations
in TET2, ASXL1, and DNMT3A are associated with not only in-
creased risk of haematologic malignancies but also increased CVD
risk.41 Patients with Clonal Haematopoiesis of Indeterminate
Potential (CHIP), in comparison to patients without clones in periph-
eral blood have higher risk of dying. This increased risk could not
only be explained by the higher incidence of haematopoietic malig-
nancy and may be related to coronary heart disease and stroke.
Clonal Haematopoiesis of Indeterminate Potential carriers have a 1.9
times greater chance of developing coronary heart disease, and a 4
times higher chance on myocardial infarction in comparison with
non-CHIP carriers.42 Possibly these clones changes the differentiation
of monocytes and macrophages and thereby aggravate atherosclero-
sis as shown in a murine model.42 In this murine model not only
increased atherosclerosis was found in TET2 mutation but also in-
creased levels of CXC chemokines, interleukin-8, and interleukin-
1b.42,43
Trained innate immunity and
epigenetic reprogramming: a
memory for innate immune cells
In the classical immunological paradigm, activation of the innate im-
mune cells (monocytes and macrophages) provides a rapid first line
defence against infectious episodes, followed by a ‘memory’ response
mediated by the adaptive immune system. Recently, Netea et al.44–46
challenged the classical dichotomy of innate vs. adaptive immunity by
showing that brief exposure to microbial products induces a long-
term pro-inflammatory phenotype in monocytes, which was found
to be linked to metabolic and epigenetic reprogramming. After vacci-
nation of healthy subjects with BCG, monocytes showed a profound
pro-inflammatory phenotype, that persisted even 3 months after vac-
cination and could be observed even several months after the initial
exposure.47,48 The concept that the innate immune system is incapa-
ble of mounting adaptive responses49 has already been contradicted
by studies showing that organisms lacking a specific immune system
are still capable of responding adaptively to infections.50 Epigenetic
reprogramming, accompanied by markers of histone modifications
such as methylation of histone 3 at lysine residue 4 (H3K4) or H3K27
acetylation, has been proposed as the molecular mechanism respon-
sible for long-term memory of innate immunity and this process has
been termed ‘trained immunity’.45,47,51
Epigenetic control denotes the regulation of gene transcription with-
out altering the nucleotide sequence of the DNA by the modification
of the chromatin structure. These modifications result in specific chro-
mosomal regions becoming more or less accessible to transcription
factors, leading to prolonged alterations in downstream gene-products.
There are many different epigenetic modifications that are tightly regu-
lated by a wide array of specific epigenetic writers and erasers that
function in a lineage specific manner.52,53 Importantly, these modifica-
tions are reversible, making chromatin modifying enzymes a potentially
interesting therapeutic target.54 The drug development area of inhibi-
tors targeting histone deacetylases (HDACs) and DNA methyltransfer-
ases (DNMTs) in various disease states is expanding rapidly;55,56
though not yet in the cardiovascular arena. Interestingly, the epigenetic
modulators suberoylanilide hydroxamic acid (SAHA, or Vorinostat)
and valproic acid (HDAC inhibitors) have already been approved by
the FDA for cancer treatment and epilepsy, respectively.57,58 In the
past years, the potential for epigenetic intervention by targeting specific
histone methyltransferases has increasingly received attention.59
In the cardiovascular domain, pro-atherogenic stimuli such as
oxLDL and lipoprotein(a) [Lp(a)] have recently been shown to in-
duce a prolonged, ‘primed’ or ‘trained’ state of the innate immune
cells, already in the plasma compartment. In patients with elevated
Lp(a), a major CV risk factor, monocytes showed a primed state by
increased pro-inflammatory cytokine production upon ex vivo
Reprogramming of monocytes and their progenitors in CID and CVD 3523
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stimulation. In vitro priming of healthy monocytes with Lp(a) showed
a training capacity: 6 days after first exposure to Lp(a), monocytes
showed an increased pro-inflammatory phenotype. In vivo, this
trained state coincided with activated monocytes which accumulated
more rapidly into the arterial wall in vivo.60 In line, oxidized LDL-c
also induced trained immunity via epigenetic reprogramming, eliciting
an activated monocyte phenotype. Incubation of monocytes with
oxLDL was associated with increased H3K4me3.40 The time course
for the induction of these pro-inflammatory changes remains to be
established. Because monocytes and macrophages have life spans in
the order of hours to days, their upstream progenitors, including
bone marrow haematopoietic progenitor cells (HSPCs) should also
be investigated. Interestingly, recent findings by van der Valk et al. and
Nahrendorf and colleagues61 did reveal a persistent inflammatory
state in the arterial wall, as well as increased metabolic activity in the
bone marrow more than 3 months after an AMI. These findings, sup-
ported by experimental data, imply that epigenetic changes in short-
lived monocytes are likely to be maintained by similar changes in the
haematopoietic precursor cells in the bone marrow (HSPC).61
Detailed in vivo studies on HSPCs are, however, absent to date.
How do these pro-atherogenic stimuli modify epigenetic markers?
Accumulating evidence points to a pivotal role for rewiring of intracellu-
lar metabolism in innate immune cells 62 Various intermediate metabo-
lites act as important cofactors for epigenetic enzymes, including
NADþ, acetylCoA, SAM, FAD, and fumarate.63–65 Trained immunity
by BCG or beta-glucan requires a shift from oxidative phosphorylation
to aerobic glycolysis.66,67 In addition, accumulation of fumarate due to
anaplerotic replenishment of the TCA cycle by glutamine projects onto
epigenetic changes by inhibition of the lysine demethylase KDM5.68 The
relevance of these metabolic changes for the development of athero-
sclerosis is illustrated by the up-regulation of glycolytic pathways in
monocytes and macrophages isolated from patients with atherosclero-
sis.69,70 For a more detailed description of the role of immunometabo-
lism in the (epigenetic) reprogramming of innate immune cells in the
context of atherosclerosis, we refer to recent excellent reviews on this
topic71 (Stienstra et al., in press).
In parallel, in CID, the increased inflammatory responsiveness of
monocytes and macrophages due to trained immunity is likely to play
a central role.72 The abundantly present danger associated molecular
patterns (DAMPs) in CID and particularly in RA, including biglycan,73
S100 proteins,74 HMBG1,75 citrullinated proteins,76 heat shock pro-
teins,77 and tenascin-C78 might induce a trained state of innate im-
mune cells, leading to prolonged hyper responsiveness mediated at
least partly via histone modifications. Interestingly, synovial fibroblasts
from affected joints in RA also showed distinct global and promoter-
specific changes in DNA methylation,79 collectively pointing towards
a role for epigenetic modulation being involved in the persistent pro-
inflammatory state in CID.
From this perspective, the capacity of innate immunity to mount
adaptive responses both redefines the function of innate immunity
and provides a potential therapeutic target in chronic inflammation, in-
cluding atherosclerosis and RA. This also echoes the highly feared re-
current CV-events in the first months after an initial CV-event,
attributed largely to persistent inflammatory activity.80 As active par-
ticipants in arterial wall inflammation, ‘trained’ innate immune cells
may represent promising therapeutic targets.81–83 Targeting innate im-
mune cells is likely to also offer a wider therapeutic window compared
to the adaptive immune system, since patients with innate immune de-
ficiencies are much less prone to infectious complications compared
to those with disturbances in the adaptive immune system.
In the Horizon2020 project REPROGRAM,84 we propose that
trained immunity is an important pathway promoting an activated
state of innate immune cells in the context of atherosclerotic CVD.
Hence, modulation of the trained immunity pathway may offer an at-
tractive strategy to effectively attenuate the chronic inflammatory
state in atherosclerosis as well as other CID (Figure 1).
Common immune responses in
atherosclerosis and chronic
inflammatory diseases
Many CIDs are associated with altered monocyte phenotype and
function, which may alter the potential of these cells to influence ath-
erogenesis.85 For example, in patients with well-controlled human
immunodeficiency virus (HIV), arterial wall inflammation in the aorta
is increased, associated with circulating markers of monocyte and
macrophage activation.86 Furthermore, resident macrophages and
TLR signalling play an important role in RA,87 atherosclerotic tissue,88
and acute coronary syndromes.89 MRP8/14, a physiological TLR4
ligand released by activated macrophages, is a prognostic biomarker
in both RA90 and acute coronary syndromes.91 In mice, experimental
osteoarthritis induced increased levels of Ly6C-high, as well as
Ly6C-low monocytes, due to increased bone marrow activity.92 It
has been recently proposed that therapeutically targeting interac-
tions between TLRs and foam cell formation may reduce adverse car-
diovascular outcomes in individuals with CID.93 These studies have
contributed to uncover novel molecular mechanisms that modulate
the inflammatory response in atherosclerotic lesions, and suggest
that a parallel exists with chronic inflammatory diseases, such as RA
(Figure 2). Particularly, a prominent role for endogenous danger
signals, comprising both pathogen-associated molecular patterns
(PAMPs) as well as DAMPs, in the immunological pathophysiology is
emerging rapidly.94,95 In RA tissues and synovial fluids, multiple
DAMPs are present, most of which have the capacity to act as TLR2
and/or TLR4 agonists.
Several DAMPs have now been shown to contribute to the
‘memory’ response in monocytes, mediated by distinct histone
modifications.96 The correlation between RA disease activity/du-
ration and the markedly increased inflammatory activity in the
arterial wall in RA patients97 lends further support to a com-
mon underlying pathophysiology, eventually translating into a
two- to three-fold higher CV-risk in RA patients which is only
partly attributable to known CV-risk factors.98 In support of im-
mune cell hyperactivity as a causal factor of CVD in patients
with RA, Bernelot Moens et al.96 recently observed that circu-
lating monocytes in RA patients in remission requiring continued
biological therapy are characterized by increased expression of
activation/adhesion markers, which coincides with increased
arterial wall inflammation in RA patients. A potential contribu-
tion of epigenetic modulation to the persistent inflammatory
state in RA as well as its cardiovascular co-morbidity has been
put forward,99 yet the evidence for this concept remains to be
delivered.
3524 R.M. Hoogeveen et al.
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..Multimodal imaging in
atherosclerosis and chronic
inflammatory diseases
The optimal method to evaluate the presence or progression of ath-
erosclerosis is to directly visualize the target organ for atherosclerosis:
the arterial wall. In line with this, several imaging modalities have been
used in patient studies to measure the dimension of the arterial wall,
including ultrasound100 and magnetic resonance imaging (MRI).101
With the new insight that inflammation is a key component dictating
both the progression of atherosclerotic lesions as well as the vulnera-
bility of advanced plaques, attention has shifted towards novel imaging
modalities able to quantify the functional aspects in the arterial wall/
atherosclerotic lesions, including the inflammatory activity. Whereas
previously, ultrasound imaging only gave information about intima
media thickness, new contrast agents have emerged in contrast-
enhanced ultrasonography (CEUS). Contrast-enhanced ultrasonogra-
phy has shown in human studies to directly visualize the vasa vasorum
in atherosclerotic carotid arteries and has the ability to show the ad-
ventitial wall and intra-plaque neovascularization. However widely
available and easily accessible, robust quantitative assessment tools of
the CEUS signal are lacking, which is a major limitation.102 Magnetic
resonance imaging gives information about both vessel wall and lumen
and can identify positive remodelling. In tracking arterial wall inflamma-
tion in MRI ultra-small super paramagnetic particles of iron oxide
(USPIOs) are used, since these are phagocytosed by macrophages.
The USPIO enhanced MRI signal does not only reflect the phagocyto-
sis, but also local haemorrhage and calcification.101 SPECT imaging us-
ing 99mTc labelling of autologous leucocytes in humans can visualize
leucocyte migration into the atherosclerotic plaque,25 but has lower
spatial resolution in comparison to PET.103 Optical coherence
tomography (OCT) is an intravascular method, using infra-red light.
Optical coherence tomography has the capacity to detect macro-
phages, however motion artefacts limits the usability.7 Positron emis-
sion tomography with computed tomography is frequently used in
clinical studies of atherosclerosis. A diversity of PET tracers have been
investigated, however 18-fluordeoxyglucose (18F-FDG) PET/CT im-
aging is increasingly applied to serve as a measure of arterial wall
inflammation.104 Although its primary target is to detect overall
metabolic activity, 18F-FDG imaging in patients with atherosclerosis
robustly correlates with macrophage density as measured by histol-
ogy105 and correlates to plaque macrophage content and distribu-
tion.106 It is increasingly used to monitor inflammation in vascular beds
Figure 1 Innate immune cell activation as a common pathway perpetuating the upheld inflammatory state in atherosclerosis and other chronic in-
flammatory disease states. Both non-modifiable (i.e. genome and gender) and modifiable (i.e. danger associated molecular patterns and pathogen-as-
sociated molecular patterns) risk factors can lead to the induction of epigenetic modifications in innate immune cells. Changes can occur in either
haematopoietic stem cells or monocytes, leading to differentiation into reprogrammed monocytes or macrophages. This results in a hyper-respon-
sive immune system, contributing to a chronic inflammatory disease state such as atherosclerotic cardiovascular diseases or chronic inflammatory dis-
eases. Current therapies aim to lower risk factors, for example by lipid lowering. Future therapies might include additional epigenetic modulators,
preventing and reversing the modification of innate immune cells, ideally by specifically targeting immune cells.
Reprogramming of monocytes and their progenitors in CID and CVD 3525
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..as a function of therapy in patients, particularly in the aorta and carotid
arteries.107–110
Clinical credence for PET-based imaging emerged after several ret-
rospective111,112 and small-scale prospective studies showing that
PET can identify active culprit lesions113,114 and predict the risk of a
recurrent event. In addition, the first intervention studies have been
performed using changes in 18F-FDG uptake PET to monitor thera-
peutic efficacy of novel anti-atherosclerotic strategies.109,115 More re-
cently, several small 18F-FDG PET/computed tomography studies in
patients with AMI reported increased PET signals in ischaemic myo-
cardial regions in association with higher 18F-FDG uptake in remote
non-culprit atherosclerotic lesions, as well as in haematopoietic
organs,116,117 highlighting the systemic inflammation following acute
ischaemic events, as previously described in pre-clinical models. A
retrospective trial in patients with atherosclerosis reported that in-
creased splenic 18F-FDG also predicted higher cardiovascular event
rates.23 These trials exemplify the opportunities generated by whole-
body imaging, including the ability to sample more than one organ
system. In order to unravel systems-wide immune actions as well as
connections between cardiovascular and haematopoietic organs,
imaging studies allow integration of data from cardiovascular organs,
non-culprit atherosclerotic lesions, spleen, and bone marrow, which
can be combined with data derived from blood and bone-marrow
analyses. In this scenario, whole-body multimodal imaging can
Figure 2 Monocyte reprogramming in atherosclerosis and chronic inflammatory diseases. Different chronic inflammatory disease states such as
myocardial infarction, stroke, rheumatoid arthritis and gout as well as different atherosclerotic danger associated molecular patterns (DAMPs) such
as low-density-lipoprotein, oxLDL, VLDL, and cholesterol crystals can trigger monocyte phenotype to change into a long-term activated monocyte.
In the bone marrow, these pathogen-associated molecular patterns and danger associated molecular patterns alter the phenotype of the haemato-
poietic stem cells (HSCs) leading to the differentiation into a different monocyte phenotype and increased monocyte accumulation in the spleen and
circulation. Furthermore, HSCs increasingly travel to the spleen leading to extramedullary haematopoiesis.
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translate preclinical findings, serve as companion imaging in clinical tri-
als, and help guide individualized therapy.
Therapeutic implications of
epigenetic reprogramming of
innate immune cells
Chronic inflammatory diseases are the most common diseases of
ageing and represent one of our major health threats. These include
most forms of CVD, RA, type 2 diabetes, and virtually all neurode-
generative diseases. In these disease states, a non-autoimmune pri-
mary pathological process determines disease progression; for
example, inflammation promotes the formation of oxidized phospho-
lipids that may serve as DAMPs in atherosclerosis.94 As with autoim-
mune diseases, inhibition of inflammation could reduce the rate of
disease progression to the point of substantial clinical benefit despite
not altering the underlying pathogenic process. In contrast, in primary
inflammatory or autoimmune diseases there is little evidence as yet
for efficacy of this approach in humans.
The increased inflammatory responsiveness of monocytes and
macrophages due to trained immunity is likely to play a central role in
CIDs. From this perspective, the adaptive capacity of the innate im-
mune system provides a potential therapeutic target in human dis-
eases. It is thus essential to improve our understanding of the
pathophysiology and cellular and molecular mechanisms common to
chronic inflammation, starting with atherosclerosis. Moreover, it is
essential to understand the cellular and molecular mechanisms that
mediate trained immunity, in hopes of harnessing their therapeutic
potential. An important finding in that respect is that trained immu-
nity is characterized by a metabolic shift from oxidative phosphoryla-
tion to aerobic glycolysis, which closely interacts with the epigenetic
reprogramming.65 This opens doors for new potential therapeutic
possibilities. To prevent training, this mechanism can be targeted, for
example using inhibitors of glycolysis,118 or inhibitors of micro RNAs
that dictate the balance between glycolysis and OXPHOS.119
New knowledge about inflammatory signalling, particularly in the
areas of endogenous homeostatic pathways and inflammation resolu-
tion also provides the promise for new therapeutic options that can
adequately meet the therapeutic challenges in CID and atherosclero-
sis. The abundant presence of epigenetic alterations in both CID and
atherosclerosis underlines the potential for clinical applications. In
line with this, the potential of epigenetic alterations as molecular bio-
markers are being explored for CVD risk evaluation, early detection,
prognosis stratification, and treatment response prediction. On the
other hand, unlike genetic mutations, epigenetic changes, including
DNA methylation and histone modifications, are pharmacologically
reversible, making them attractive targets in therapeutic strategies.
Novel insights that will develop by a systems biology approach of
trained monocytes is highly likely to identify novel therapeutic targets
to prevent or treat atherosclerosis.80 Several preclinical studies have
already provided proof-of-concept data that drugs that modulate the
activity of epigenetic writers or erasers, such as HDAC inhibitors,
can modulate the development of atherosclerosis.120,121
Furthermore, BET-inhibitors such as RVX-208, JQ1, and I-Bet that in-
hibit the interaction of BET proteins with acetylated histone tails,
showed a repression of pathways that contribute to CVD and inhibi-
tion of atherogenesis in mouse models.122–124 Drugs leading to the
reverse reprogramming of macrophages are for example cyclodex-
trin. Via the LXR pathway, cyclodextrin supports atherosclerosis re-
gression by transcriptional reprogramming leading to increased
cholesterol efflux and anti-inflammatory effects,7 thereby reversing
the initial pro-inflammatory response upon cholesterol crystal accu-
mulation. Major advances have been made in the field of oncology
with aberrant DNA methylation profiles and alterations in histone
modification being linked to specific cancers and tumour progression,
some of which are already used in the clinic.125 The discrepancy be-
tween major advances in the oncology field and scarcity of data in the
cardiovascular and rheumatology field illustrates that an organized
effort to address the potential of epigenetic modulation in athero-
sclerosis and CID is long overdue.
In conclusion, epigenetic reprogramming has been shown to play a
role in perpetuation of the chronic inflammatory state in atheroscle-
rosis by promoting activation of innate immune cells. Since innate im-
mune cell activation serves as a mostly inappropriate amplification
loop which is not critically involved in primary defence against infec-
tious diseases, this novel pathway may offer a safe and novel method
to lower this redundant inflammatory activity in absence of the dan-
ger of eliciting immune suppression. Therefore, further research is
warranted to better understand cellular and molecular mechanisms
mediating trained immunity, offering the opportunity of opening this
area for future therapeutic agents in the cardiovascular area.
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